{"id":"NCT02531438","sponsor":"Paratek Pharmaceuticals Inc","briefTitle":"Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)","officialTitle":"A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-11","primaryCompletion":"2017-02-05","completion":"2017-03-10","firstPosted":"2015-08-24","resultsPosted":"2018-11-29","lastUpdate":"2019-01-16"},"enrollment":774,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Bacterial Pneumonia","Community-Acquired Infections"],"interventions":[{"type":"DRUG","name":"Omadacycline","otherNames":[]},{"type":"DRUG","name":"Moxifloxacin","otherNames":["Avelox"]}],"arms":[{"label":"Omadacycline","type":"EXPERIMENTAL"},{"label":"Moxifloxacin","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to moxifloxacin in the treatment of adults with community-acquired bacterial pneumonia.","primaryOutcome":{"measure":"Number of Participants With Early Clinical Response","timeFrame":"Screening; 72 to 120 hours after the first dose of test article","effectByArm":[{"arm":"Omadacycline","deltaMin":313,"sd":null},{"arm":"Moxifloxacin","deltaMin":321,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":5},"locations":{"siteCount":140,"countries":["United States","Belgium","Brazil","Bulgaria","Croatia","Czechia","Georgia","Germany","Greece","Hungary","Israel","Latvia","Mexico","Peru","Philippines","Poland","Romania","Russia","Slovakia","South Africa","South Korea","Spain","Taiwan","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["37575994","35776862","33326848","31367741","30726692"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":382},"commonTop":["Diarrhea","Alanine aminotransferase increased","Nausea","Hypertension","Aspartate aminotransferase increased"]}}